Travere Therapeutics (TVTX) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Travere Therapeutics (TVTX) Company Statistics | The Fly

Travere Therapeutics

· TVTX

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

5.655 B

-1.85%

General

Market Cap: $5.65B
Enterprise Value: $5.97B
Shares Outstanding: 92,990,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 94.41%
Operating Margin: -6.84%
Net Profit Margin: -7.35%
FCF Margin: 8.71%
ROA: -5.44%
ROE: -55.79%
ROIC: -6.19%
Current Ratio: 4.05
Debt-to-Equity: 25.16
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: 9.26
P/FCF: 106.28
P/B: 223.29
EV/EBITDA: 3869.55

Growth

Rev 1Y: 110.45%
Rev 1Y Fwd Est: 47.66%
Rev 3Y (CAGR): 64.89%
Rev 5Y (CAGR): 19.87%

Income Statement (TTM)

Revenue: $591.33M
Gross Margin: 94.41%
Operating Expenses: $598.71M
Operating Income: -$40.46M
Net Profit: -$43.46M

Balance Sheet

Rev 10Y (CAGR)

17.25%

EPS 1Y

—

EPS 1Y Fwd Est

—

EPS 3Y (CAGR)

—

EPS 5Y (CAGR)

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $117.74M
Working Capital: $463.12M
Total Assets: $799.36M
Net Debt: $499.17M
Total Liabilities: $774.84M
Total Equity: $24.52M

Cash Flow Statement (TTM)

Cash Flow from Operations: $92.7M
Cash Flow from Investing: -$202.99M
Cash Flow from Financing: $153.06M
Free Cash Flow: $51.52M
Capital Expenditures: $41.18M